These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 26356148)

  • 1. A simulation system for biomarker evolution in neurodegenerative disease.
    Young AL; Oxtoby NP; Ourselin S; Schott JM; Alexander DC;
    Med Image Anal; 2015 Dec; 26(1):47-56. PubMed ID: 26356148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal Trajectory and Progression Score Estimation from Voxelwise Longitudinal Imaging Measures: Application to Amyloid Imaging.
    Bilgel M; Jedynak B; Wong DF; Resnick SM; Prince JL
    Inf Process Med Imaging; 2015; 24():424-36. PubMed ID: 26221692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Orderings of Events in Disease Progression.
    Young AL; Oxtoby NP; Huang J; Marinescu RV; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Inf Process Med Imaging; 2015; 24():711-22. PubMed ID: 26223048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainty and sensitivity analysis of biokinetic models for radiopharmaceuticals used in nuclear medicine.
    Li WB; Hoeschen C
    Radiat Prot Dosimetry; 2010; 139(1-3):228-31. PubMed ID: 20185457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biophysical model of brain deformation to simulate and analyze longitudinal MRIs of patients with Alzheimer's disease.
    Khanal B; Lorenzi M; Ayache N; Pennec X
    Neuroimage; 2016 Jul; 134():35-52. PubMed ID: 27039699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies.
    Strauss LG; Pan L; Cheng C; Haberkorn U; Dimitrakopoulou-Strauss A
    J Nucl Med; 2011 Mar; 52(3):379-85. PubMed ID: 21321263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying metabolic asymmetry modulo structure in Alzheimer's disease.
    Fletcher PT; Powell S; Foster NL; Joshi SC
    Inf Process Med Imaging; 2007; 20():446-57. PubMed ID: 17633720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling.
    Venkatraghavan V; Bron EE; Niessen WJ; Klein S;
    Neuroimage; 2019 Feb; 186():518-532. PubMed ID: 30471388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcortical elevation of metabolism in Parkinson's disease--a critical reappraisal in the context of global mean normalization.
    Borghammer P; Cumming P; Aanerud J; Förster S; Gjedde A
    Neuroimage; 2009 Oct; 47(4):1514-21. PubMed ID: 19465133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data.
    Gatidis S; Würslin C; Seith F; Schäfer JF; la Fougère C; Nikolaou K; Schwenzer NF; Schmidt H
    Hell J Nucl Med; 2016; 19(1):15-8. PubMed ID: 26929936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DIVE: A spatiotemporal progression model of brain pathology in neurodegenerative disorders.
    Marinescu RV; Eshaghi A; Lorenzi M; Young AL; Oxtoby NP; Garbarino S; Crutch SJ; Alexander DC;
    Neuroimage; 2019 May; 192():166-177. PubMed ID: 30844504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplifications in analyzing positron emission tomography data: effects on outcome measures.
    Logan J; Alexoff D; Kriplani A
    Nucl Med Biol; 2007 Oct; 34(7):743-56. PubMed ID: 17921027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians].
    Trombella S; Assal F; Zekry D; Gold G; Giannakopoulos P; Garibotto V; Démonet JF; Frisoni GB
    Rev Med Suisse; 2016 Apr; 12(515):795-8. PubMed ID: 27276723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of arterial input functions for dual pharmacokinetic modeling using Gd-DTPA/MRI and 18F-FDG/PET.
    Poulin E; Lebel R; Croteau E; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
    Magn Reson Med; 2013 Mar; 69(3):781-92. PubMed ID: 22570280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model.
    Song SL; Deng C; Wen LF; Liu JJ; Wang H; Feng D; Wong CY; Huang G
    Nucl Med Biol; 2010 Apr; 37(3):327-33. PubMed ID: 20346872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging plus X: multimodal models of neurodegenerative disease.
    Oxtoby NP; Alexander DC;
    Curr Opin Neurol; 2017 Aug; 30(4):371-379. PubMed ID: 28520598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulating neurodegeneration through longitudinal population analysis of structural and diffusion weighted MRI data.
    Modat M; Simpson IJ; Cardoso MJ; Cash DM; Toussaint N; Fox NC; Ourselin S
    Med Image Comput Comput Assist Interv; 2014; 17(Pt 3):57-64. PubMed ID: 25320782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STGP: Spatio-temporal Gaussian process models for longitudinal neuroimaging data.
    Hyun JW; Li Y; Huang C; Styner M; Lin W; Zhu H;
    Neuroimage; 2016 Jul; 134():550-562. PubMed ID: 27103140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the effect of sample size of the normal database on statistical power of single subject analysis.
    Buchert R
    Nucl Med Commun; 2008 Sep; 29(9):837. PubMed ID: 18677213
    [No Abstract]   [Full Text] [Related]  

  • 20. Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease.
    Budgeon CA; Murray K; Turlach BA; Baker S; Villemagne VL; Burnham SC;
    Stat Med; 2017 Jul; 36(17):2720-2734. PubMed ID: 28444781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.